Allergic Disorders

The sBLA is supported by data from Studies A and B of phase 3 LIBERTY-CUPID trial which included patients with CSU who were inadequately controlled on standard-of-care H1 antihistamines.

Updated review reveals supplementation does not impact rate of exacerbations requiring systemic corticosteroids

18.9 percent of children and 25.7 percent of adults had seasonal allergy; 10.8 and 7.3 percent had eczema in 2021

Odactra is an allergen extract indicated as immunotherapy for the treatment of HDM-induced allergic rhinitis.

Lower use of psychotropic, antihypertensive, and asthma medications observed; association attenuated by body mass index

Multiple biopsies of duodenum needed for diagnosis of celiac disease; upper endoscopy with intestinal biopsy useful for monitoring cases on gluten-free diet

Increases seen compared with states where neither recreational nor medical legalization has occurred

Association seen between infant exposure to acid-suppressive medications and increased asthma risk in offspring

Red flags include pharmacies that do not require a doctor’s prescription or have a licensed pharmacist to answer questions

The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.

The researchers analyzed 351,870 US patients at least 12 years of age from the IBM MarketScan databases who received SABA for asthma from 2010 to 2017.

Investigators assessed the annualized asthma exacerbation rate (AAER) and the annualized rate of asthma exacerbations requiring hospitalization over 52 weeks.

Investigators found the association between food allergy at 3 to 5 years of age and the risk of ever having asthma by 10 years of age was significantly modified by having atopic dermatitis.

Researchers conducted on a pooled safety analysis of lebrikizumab during the 52-week placebo-controlled period.

About 67% of children in the active peanut patch cohort and 33.5% in the placebo patch cohort achieved the primary efficacy endpoint.

The primary outcome was to compare dupilumab, benralizumab, and mepolizumab in patients with at least 2 pre-index exacerbations.

“A needle-free option for administering epinephrine would be used more quickly after symptoms developed and would be easier to use versus an injectable device.”

Researchers found a statistically significant 73% lower HAE attack rate per 28 days with lanadelumab 300mg taken every 2 weeks vs daily berotralstat 150mg over 48 weeks.

The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.

Intranasal epinephrine was found to be absorbed quicker.